Becton Dickinson

Alere received FDA 510(k) clearances for four tests, including those for influenza A and B, strep A, and RNA-based respiratory syncytial virus.

The firm saw revenue growth across all segments, with diagnostic systems revenues increasing 14 percent.

The BD MAX Check-Points CPO assay detects common carbapenemase-producing organisms in less than 2.5 hours.

The FDA said it observed a number of violations of federal law related to the company's Vacutainer blood collection tubes during an inspection.

The investment bank noted that Hologic could be the "biggest beneficiary from tax reform" in its coverage with a potential 8 percent benefit to earnings per share.

The Federal Trade Commission said today that Becton Dickinson and CR Bard have agreed to divest two medical device product lines to settle its complaint that the proposed $24-billion acquisition would negatively impact competition.

The results reflected the divesture of the firm's respiratory solutions business. The firm beat the consensus Wall Street estimates on the top and bottom lines.